Novel Arginine-containing Macrocyclic MMP Inhibitors: Synthesis, ^99mTc-labeling, and Evaluation

Area of Science:

• Biochemistry
• Medicinal Chemistry
• Molecular Imaging

Background:

• Matrix metalloproteinases (MMPs) play a crucial role in tissue remodeling.
• MMP inhibitors and radiolabeled analogs are vital for disease imaging and therapy.

Purpose of the Study:

• To design, synthesize, and evaluate a novel Arginine-containing macrocyclic hydroxamate analog (RYM) and its 99mTc-labeled conjugate (99mTc-RYM1).
• To assess the potential of 99mTc-RYM1 for molecular imaging of MMP activity in disease states.

Main Methods:

• Synthesis and characterization of RYM and its conjugate RYM1.
• In vitro inhibition assays against recombinant human MMPs.
• Radiolabeling of RYM1 with 99mTc and assessment of radiochemical purity and yield.
• Evaluation of 99mTc-RYM1 binding in lung tissue from IL-13 transgenic mice.

Main Results:

• RYM demonstrated potent inhibition of multiple recombinant human MMPs.
• RYM1 was efficiently labeled with 99mTc, yielding high radiochemical purity and yield.
• 99mTc-RYM1 showed specific binding to lung tissue with increased MMP activity.
• RYM1 and its radiolabeled product maintained similar inhibition potencies against MMP-12.

Conclusions:

• The novel water-soluble Arginine-containing macrocyclic hydroxamate, 99mTc-RYM1, is a promising agent for MMP-targeted molecular imaging.
• This compound holds potential for targeted imaging and therapy in diseases characterized by MMP-driven tissue remodeling and inflammation.